Clarity Pharmaceuticals SECuRE Trial Update
Key points
- Preliminary assessment of 8 GBq 67Cu-SAR-bisPSMA shows promising results
- 74% of participants achieved PSA25, 63% achieved PSA50
- Two new complete responses observed, bringing total to seven
- Favourable safety profile with mostly mild to moderate adverse events
Full summary
Clarity Pharmaceuticals Ltd. has announced preliminary results from the SECuRE trial evaluating the 8 GBq dose of 67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer (mCRPC) patients. The assessment, based on 19 participants, shows substantial PSA reductions with 74% achieving PSA25, 63% achieving PSA50, and 53% achieving PSA75. Additionally, 81% of evaluable participants achieved disease control, with 31% achieving complete response or undetectable disease. Notably, two new complete responses were observed, bringing the total to seven participants across the 67Cu-SAR-bisPSMA program. The treatment demonstrated a favorable safety profile with mostly mild to moderate adverse events.
Summary generated by a large language model. Please interpret with care.